This was further demonstrated by the suppression of CSN5-mediated reduction in PD-L-1 expression in cancer cells, which increased the reactivity of the cells to anti-CTLA4 treatment (18) (Figure 2B). This evidence concerns the gene CTLA4 and cancer.